[ CAS No. 41762-76-9 ] {[proInfo.proName]}

Name: 41762-76-9|3-(Methylsulfonyl)-2-oxoimidazolidine-1-carbonyl chloride|98%
Brand: Ambeed
SKU: A614135
Rating: 96 (30 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

2D 3D

Structure of 41762-76-9 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 41762-76-9 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 41762-76-9 ]

SDS Specification

Alternatived Products of [ 41762-76-9 ]

Product Details of [ 41762-76-9 ]

CAS No. :	41762-76-9	MDL No. :	MFCD00272360
Formula :	C₅H₇ClN₂O₄S	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	ZWTPALHHEULAPI-UHFFFAOYSA-N
M.W :	226.64	Pubchem ID :	3016299
Synonyms :

Calculated chemistry of [ 41762-76-9 ]

Physicochemical Properties

Num. heavy atoms :	13
Num. arom. heavy atoms :	0
Fraction Csp3 :	0.6
Num. rotatable bonds :	2
Num. H-bond acceptors :	4.0
Num. H-bond donors :	0.0
Molar Refractivity :	52.6
TPSA :	83.14 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-7.74 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.71
Log Po/w (XLOGP3) :	-0.08
Log Po/w (WLOGP) :	0.36
Log Po/w (MLOGP) :	-1.16
Log Po/w (SILICOS-IT) :	-1.09
Consensus Log Po/w :	-0.25

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.06
Solubility :	19.6 mg/ml ; 0.0865 mol/l
Class :	Very soluble
Log S (Ali) :	-1.21
Solubility :	13.8 mg/ml ; 0.0611 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-0.16
Solubility :	158.0 mg/ml ; 0.697 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	2.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.66

Safety of [ 41762-76-9 ]

Signal Word:	Danger	Class:	8
Precautionary Statements:	P280-P305+P351+P338-P310	UN#:	3261
Hazard Statements:	H314	Packing Group:	Ⅱ
GHS Pictogram:

Application In Synthesis of [ 41762-76-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 41762-76-9 ]
Downstream synthetic route of [ 41762-76-9 ]

[ 41762-76-9 ] Synthesis Path-Upstream 1~4

1
[ 75-44-5 ]
[ 41730-79-4 ]
[ 41762-76-9 ]

Reference： [1] Patent: US3972869, 1976, A,
[2] Patent: US3983105, 1976, A,
[3] Patent: US3972870, 1976, A,
[4] Patent: US3978056, 1976, A,
[5] Patent: US3974141, 1976, A,
[6] Patent: US3974142, 1976, A,
[7] Arzneimittel Forschung, 1983, vol. 33, # 1, p. 88 - 90

2
[ 41730-79-4 ]
[ 503-38-8 ]
[ 41762-76-9 ]

Reference： [1] Organic Preparations and Procedures International, 2000, vol. 32, # 5, p. 498 - 501

3
[ 32315-10-9 ]
[ 41730-79-4 ]
[ 41762-76-9 ]

Reference： [1] Journal of Chemical Research - Part S, 2000, # 9, p. 440 - 441

4
[ 41762-76-9 ]
[ 42057-22-7 ]

Reference： [1] Arzneimittel Forschung, 1983, vol. 33, # 1, p. 88 - 90

[ 41762-76-9 ] Synthesis Path-Downstream 1~39

1
[ 75-44-5 ]
[ 41730-79-4 ]
[ 41762-76-9 ]

Yield	Reaction Conditions	Operation in experiment
70%	In 1,4-dioxane;	C. 1-Chlorocarbonyl-3-methylsulphonyl-imidazolidone-(2) SPC98 16.4 parts by weight of 1-methylsulphonyl-imidazolidone-(2) in dioxane were boiled for 3 days with 27 parts by weight of trimethylchlorosilane and 20 parts by weight of triethylamine. The triethylamine hydrochloride which had precipitated was filtered off, 11 parts by weight of phosgene were added and the mixture was left to stand overnight at room temperature. Thereafter it was evaporated to dryness and the product was recrystallized from boiling acetone. Yield 70 %. Melting point = 178 C Calculated: C, 26.5; H, 3.1; Cl, 15.7; N, 12.4; S, 14.1. Found: C, 27.2; H, 3.4; Cl, 15.3; N, 12.0; S, 14.1. NMR-signals at tau = 5.6 - 6.2 (4H), and 6.6 ppm (3H). IR-bands at 3010, 1807, 1721, 1360, 1165, 984 and 742 cm-1.
70%	In 1,4-dioxane;	C. 1-Chlorocarbonyl-3-methylsulphonyl-imidazolidone-(2): EQU90 16.4 parts by weight of 1-methylsulphonyl-imidazolidone-(2) in dioxane were boiled for 3 days with 27 parts by weight of trimethylchlorosilane and 20 parts by weight of triethylamine. The triethylamine hydrochloride which had precipitated was filtered off, 11 parts by weight of phosgene were added and the mixture was left to stand overnight at room temperature. Thereafter it was evaporated to dryness and the product was recrystallized from boiling acetone. Yield 70 %. Melting point = 178 C Calculated: C 26.5; H 3.1; Cl 15.7; N 12.4; S 14.1; Found: C 27.2; H 3.4; Cl 15.3; N 12.0; S 14.1; NMR-signals at tau = 5.6 - 6.2 (4H), and 6.6 ppm (3H). IR-bands at 3010, 1807, 1721, 1360, 1165, 984 and 742 cm-1.
70%	In 1,4-dioxane;	C. 1-Chlorocarbonyl-3-methylsulphonyl-imidazolidone-(2) SPC99 16.4 parts by weight of 1-methylsulphonyl-imidazolidone-(2) in dioxane were boiled for 3 days with 27 parts by weight of trimethylchlorosilane and 20 parts by weight of triethylamine. The triethylamine hydrochloride which had precipitated was filtered off, 11 parts by weight of phosgene were added and the mixture was left to stand overnight at room temperature. Thereafter it was evaporated to dryness and the product was recrystallized from boiling acetone. Yield 70 %. Melting point = 178 C Calculated: C, 26.5; H, 3.1; Cl, 15.7; N, 12.4; S, 14.1. Found: C, 27.2; H, 3.4; Cl, 15.3; N, 12.0; S, 14.1. NMR-signals at tau = 5.6 - 6.2 (4H), and 6.6 ppm (3H). IR-bands at 3010, 1807, 1721, 1360, 1165, 984 and 742 cm-1.

70%

In 1,4-dioxane;

C. 1-Chlorocarbonyl-3-methylsulphonyl-imidazolidone-(2) SPC110 16.4 parts by weight of 1-methylsulphonyl-imidazolidone-(2) in dioxane were boiled for 3 days with 27 parts by weight of trimethylchlorosilane and 20 parts by weight of triethylamine. The triethylamine hydrochloride which had precipitated was filtered off, 11 parts by weight of phosgene were added and the mixture was left to stand overnight at room temperature. Thereafter it was evaporated to dryness and the product was recrystallized from boiling acetone. Yield 70 %. Melting point = 178 C Calculated: C, 26.5; H, 3.1; Cl, 15.7; N, 12.4; S, 14.1. Found: C, 27.2; H, 3.4; Cl, 15.3; N, 12.0; S, 14.1. NMR-signals at tau = 5.6 - 6.2 (4H), and 6.6 ppm (3H). IR-bands at 3010, 1807, 1721, 1360, 1165, 984 and 742 cm-1.

Reference： [1]Patent: US3972869,1976,A
[2]Patent: US3983105,1976,A
[3]Patent: US3972870,1976,A
[4]Patent: US3978056,1976,A
[5]Arzneimittel-Forschung/Drug Research,1983,vol. 33,p. 88 - 90

2
[ 875-74-1 ]
[ 41762-76-9 ]
[ 42057-28-3 ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1983,vol. 33,p. 88 - 90

3
[ 69-53-4 ]
[ 41762-76-9 ]
[ 51481-65-3 ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1983,vol. 33,p. 88 - 90

4
[ 86062-41-1 ]
[ 41762-76-9 ]
[ 86070-27-1 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1987,p. 45 - 56

Yield	Reaction Conditions	Operation in experiment
70%		B. 1-Chlorocarbonyl-3-methylsulphonyl-imidazolid-2-one EQU33 16.4 parts by weight of 1-methylsulphonyl-imidazolid-2-one in dioxane were boiled for 3 days with 27 parts by weight of trimethylchlorosilane and 20 parts by weight of triethylamine. The triethylamine hydrochloride which precipitated was filtered off, 11 parts by weight of phosgene were added to the filtrate and the mixture was left to stand overnight at room temperature. It was then evaporated to dryness and the residue recrystallized from boiling acetone. Yield: 70% Melting point = 178 Calculated: C 26.5 H 3.1 Cl 15.7 N 12.4 S 14.1 Found: C 27.2 H 3.4 Cl 15.3 N 12.0 S 14.1 NMR-signals at tau = 5.6-6.2 (4H) and 6.6 ppm (3H). IR-bands at 3010, 1807, 1721, 1360, 1165, 984 and 742 cm-1.
		The following compounds are representative of those of the formula III: ... 1-chlorocarbonyl-2-oxo-3-ethyl-imidazolidine; 1-azidocarbonyl-2-oxo-3-ethyl-imidazolidine; 1-chlorocarbonyl-2-oxo-3-phenyl-imidazolidine; 1-azidocarbonyl-2-oxo-3-phenyl-imidazolidine; 1-chlorocarbonyl-2-oxo-3-methylsulphonyl-imidazolidine; 1-chlorocarbonyl-2-oxo-3-cyanomethylsulphonyl-imidazolidine; 1-chlorocarbonyl- 2-oxo-3-beta-cyanoethylsulphonyl-imidazolidine; 1-chlorocarbonyl-2-oxo-3-trifluoromethylsulphonyl-imidazolidine; ...
		The following compounds are representative of those of the formula III: ... 1-chlorocarbonyl-2-oxo-3-ethyl-imidazolidine; 1-azidocarbonyl-2-oxo-3-ethyl-imidazolidine; 1-chlorocarbonyl-2-oxo-3-phenyl-imidazolidine; 1-azidocarbonyl-2-oxo-3-phenyl-imidazolidine; 1-chlorocarbonyl-2-oxo-3-methylsulphonyl-imidazolidine; 1-chlorocarbonyl-2-oxo-3-cyanomethylsulphonyl-imidazolidine; 1-chlorocarbonyl-2-oxo-3-beta-cyanoethylsulphonyl-imidazolidine; 1-chlorocarbonyl-2-oxo-3-trifluoromethylsulphonyl-imidazolidine; ...

EXAMPLE 22 Preparation of 3-(methylsulfonyl)imidazolidine-2-one-1-ylcarbonyl chloride To a suspension of 10.7 g. of imidazolidone-2 in 100 ml. of dry THF were added dropwise with stirring at room temperature 15.7 g. of methanesulfonyl chloride. The reaction mixture was stirred for one-hour at about 40 C. and was then heated at the reflux temperature for one-hour. The reaction mixture was evaporated in vacuo and the thick syrupy residue was dried in vacuo for about 18 hours. The dried residue was crystallized from warm acetone to yield 7.1 g. of N-methylsulfonyl-imidazolidone-2. The percent elemental composition of the product was determined by microanalysis: Calculated for: C4 H8 N2 O3 S: Theory: C, 29.26; H, 4.91; N, 17.06; S, 19.53; Found: C, 29.47; H, 4.96; N, 17.17; S, 19.50.

6
[ 41730-79-4 ]
[ 503-38-8 ]
[ 41762-76-9 ]

Reference： [1]Organic Preparations and Procedures International,2000,vol. 32,p. 498 - 501

7
[ 32315-10-9 ]
[ 41730-79-4 ]
[ 41762-76-9 ]

Reference： [1]Journal of Chemical Research - Part S,2000,p. 440 - 441

8
[ 882-33-7 ]
[ 41762-76-9 ]
3-methanesulfonyl-2-oxo-imidazolidine-1-carbothioic acid S-phenyl ester [ No CAS ]

Reference： [1]Journal of Chemical Research - Part S,2002,p. 442 - 443

9
[ 1142-19-4 ]
[ 41762-76-9 ]
3-methanesulfonyl-2-oxo-imidazolidine-1-carbothioic acid S-(4-chloro-phenyl) ester [ No CAS ]

Reference： [1]Journal of Chemical Research - Part S,2002,p. 442 - 443

10
[ 20333-40-8 ]
[ 41762-76-9 ]
3-methanesulfonyl-2-oxo-imidazolidine-1-carboselenoic acid Se-butyl ester [ No CAS ]

Reference： [1]Journal of Chemical Research - Part S,2002,p. 168 - 169

11
[ 103-19-5 ]
[ 41762-76-9 ]
3-methanesulfonyl-2-oxo-imidazolidine-1-carbothioic acid S-p-tolyl ester [ No CAS ]

Reference： [1]Journal of Chemical Research - Part S,2002,p. 442 - 443

12
[ 69468-42-4 ]
[ 41762-76-9 ]
3-methanesulfonyl-2-oxo-imidazolidine-1-carboselenoic acid Se-m-tolyl ester [ No CAS ]

Reference： [1]Journal of the Indian Chemical Society,2002,vol. 79,p. 437 - 439

13
[ 1666-13-3 ]
[ 41762-76-9 ]
3-methanesulfonyl-2-oxo-imidazolidine-1-carboselenoic acid Se-phenyl ester [ No CAS ]

Reference： [1]Journal of Chemical Research - Part S,2002,p. 168 - 169
[2]Journal of the Indian Chemical Society,2002,vol. 79,p. 437 - 439

14
[ 31121-19-4 ]
[ 41762-76-9 ]
3-methanesulfonyl-2-oxo-imidazolidine-1-carbothioic acid S-(2-chloro-phenyl) ester [ No CAS ]

Reference： [1]Journal of Chemical Research - Part S,2002,p. 442 - 443

15
[ 71112-91-9 ]
[ 41762-76-9 ]
3-methanesulfonyl-2-oxo-imidazolidine-1-carbothioic acid S-(2-bromo-phenyl) ester [ No CAS ]

Reference： [1]Journal of Chemical Research - Part S,2002,p. 442 - 443

16
[ 38762-70-8 ]
[ 41762-76-9 ]
3-methanesulfonyl-2-oxo-imidazolidine-1-carboselenoic acid Se-(4-methoxy-phenyl) ester [ No CAS ]

Reference： [1]Journal of the Indian Chemical Society,2002,vol. 79,p. 437 - 439

17
[ 41762-76-9 ]
[ 42057-22-7 ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1983,vol. 33,p. 88 - 90

18
[ 41762-76-9 ]
Mezlocillin-Natrium-Penilloat [ No CAS ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1983,vol. 33,p. 88 - 90

19
[ 41762-76-9 ]
Mezlocillin-Dinatriumpenicilloat [ No CAS ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1983,vol. 33,p. 88 - 90

20
[ 684284-62-6 ]
[ 41762-76-9 ]
C₃₆H₂₇FN₄O₈S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
75%	With triethylamine; In dichloromethane; at 20℃; for 0.0833333h;	Monophenol 45 (0.035 g, 0.0694 mmol) was dissolved in 1 mL dry dichloroethane. To this was added triethylamine (0.038 mL, 0.277 mmol) and 3-chlorocarbonyl-1- methanesulfonyl-2-imidazolidinone (0.0314 g, 0.1388 mmol Stirred at room temperature for five minutes. Dilute with dichloromethane, washed with saturated NaHCO3 solution and saturated NH4C1 solution, dried (MgSO4), concentrated to give crude. Chromatographed (10% methanol/45 % ethylacetate/45% hexanes) to give product 82 (0.036 g, 0.0518 mmol, 75%.) 1H NMR (CDCl3) 9.16 (dd, 1H), 8.49 (dd, 1H), 8.00 (s, 1H), 7.66 (dd, 1H), 7.61 (d, 4H), 7.40 (dd, 2H), 7.27 (m, 6H), 7.05 (dd, 2H), 4.81 (s, 2H), 4.2 (dd, 2H), 4.08 (dd, 2H), 3.92 (s, 3H). MS: 695 (M+1).
75%	With triethylamine; In 1,2-dichloro-ethane; at 20℃; for 0.0833333h;	Monophenol 45 (0.035 g, 0.0694 mmol) was dissolved in 1 mL dry dichloroethane. To this was added triethylamine (0.038 mL, 0.277 mmol) and 3- chlorocarbonyl-1-methanesulfonyl-2-imidazolidinone (0.0314 g, 0.1388 mmol Stirred at room temperature for five minutes. Dilute with dichloromethane, washed with saturated NaHC03 solution and saturated NH4CI solution, dried (MgS04), concentrated to give crude. Chromatographed (10% methanol/ 45 % ethylacetate/ 45% hexanes) to give product 82 (0.036 g, 0.0518 mmol, 75%. ) ¹H NMR (CDC13) 9.16 (dd, 1H), 8.49 (dd, 1H), 8.00 (s, 1H), 7.66 (dd, 1H), 7.61 (d, 4H), 7.40 (dd, 2H), 7.27 (m, 6H), 7.05 (dd, 2H), 4.81 (s, 2H), 4.2 (dd, 2H), 4.08 (dd, 2H), 3.92 (s, 3H). MS: 695 (M+1).

Reference： [1]Patent: WO2004/35576,2004,A2 .Location in patent: Page 200;201
[2]Patent: WO2005/117904,2005,A2 .Location in patent: Page/Page column 436-437

21
[ 50499-25-7 ]
[ 41762-76-9 ]
DL-2-[2-Oxo-3-methylsulphonylimidazolidin-1-ylcarbonylamino]-2-(thiazol-4-yl)acetic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydroxide; In water;	(a) DL-2-[2-Oxo-3-methylsulphonylimidazolidin-1-ylcarbonylamino]-2-(thiazol-4-yl)acetic acid DL-2-Amino-2-(thiazol-4-yl)acetic acid (214 mg) [prepared by the method described in J. Med. Chem. 16, 978 (1973)] was taken up in water (10 ml) and the pH was adjusted to 6.5 by the addition of 2N sodium hydroxide solution. 2-Oxo-3-methylsulphonylimidazolidin-1-ylcarbonyl chloride (310 mg) was added to the stirred solution at room temperature in portions; the pH being maintained between 6.0 and 7.0 by the addition of 2N sodium hydroxide solution. When the addition was complete, the mixture was stirred for one hour, filtered, and the filtrate was washed with ethyl acetate (220 ml), acidified to pH 1.0, and extracted with ethyl acetate (220 ml). The combined extracts were washed with saturated sodium chloride solution (20 ml), dried (MgSO4), filtered and evaporated to dryness in vacuo. The residue was triturated with methylene chloride and the solid product was separated by filtration to give the title compound as a white solid, (250 mg). NMR (DMSO-d6), delta=3.34 (s, 3H); 3.77 (m, 4H); 5.59 (d, 1H, J=6 Hz); 7.79 (s, 1H); 8.76 (d, 1H, J=6 Hz); 9.09 (s, 1H).

Reference： [1]Patent: US4684642,1987,A

22
[ 72-19-5 ]
[ 41762-76-9 ]
(2R,3S)-3-Hydroxy-2-(2-oxo-3-methanesulphonylimidazolidin-1-ylcarbonylamino)butanoic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydroxide; In tetrahydrofuran; water; acetone;	(a) (2R,3S)-3-Hydroxy-2-(2-oxo-3-methanesulphonylimidazolidin-1-ylcarbonylamino)butanoic acid D-Threonine (5.0 g) was suspended in water (50 ml) and treated with 2M aqueous sodium hydroxide solution to pH 10, forming a clear solution. The pH was then re-adjusted to 7.5 with concentrated hydrochloric acid and the still clear solution cooled to 15. 3-Methanesulphonyl-2-oxoimidazolidine-1-carbonyl chloride (9.5 g) was then added portionwise over 2 minutes, with simultaneous addition of 2M aqueous sodium hydroxide to maintain the pH at 6.0-7.5. Following this, acetone (30 ml) was added to give a clear solution which was then stirred at room temperature for 1 hour whilst still maintaining the pH at 6.0-7.5. After evaporation of the acetone in vacuo the aqueous residue was extracted well with ethyl acetate and the organic extracts were discarded. The pH of the aqueous phase was then adjusted to 1.5 with concentrated hydrochloric acid and the mixture was extracted using 3*50 ml portions of ethyl acetate:tetrahydrofuran (1:1). The organic extracts were dried and the solvent was evaporated to give the title compound as a white solid, (7.3 g). I.R. (KBr) 1735 cm-1.

Reference： [1]Patent: US4684641,1987,A

23
[ 41762-76-9 ]
DL-2-[2-oxo-3-methylsulphonylimidazolidin-1-ylcarbonylamino]-2-(1,2,3-thiadiazol-4-yl)acetic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		(b) DL-2-[2-oxo-3-methylsulphonylimidazolidin-1-ylcarbonylamino]-2-(1,2,3-thiadiazol-4-yl)acetic acid The title compound (1.3 g) was prepared from the amino acid of Example 3(a) (900 mg) and <strong>[41762-76-9]2-oxo-3-methylsulphonylimidazolidin-1-ylcarbonyl chloride</strong> (1.04 g) by the method of Example 1(a). NMR (DMSO-d6) delta=3.34 (s, 3H); 3.76 (m, 4H); 6.02 (d, 1H, J=6 Hz); 8.96 (d, 1H, J=6 Hz); 9.26 (s, 1H).

Reference： [1]Patent: US4684642,1987,A

24
7-(α-amino)phenylacetamido-3-(4-methyl-5-oxo-6-hydroxy-4,5-dihydro-1,2,4-triazin-3-ylthio)methyl-3-cephem-4-carboxylic acid [ No CAS ]
[ 13435-12-6 ]
[ 41762-76-9 ]
7-α-(3-methanesulfonylimidazolidine-2-one-1-ylcarbonylamino)phenylacetamido-3-(4-methyl-5-oxo-6-hydroxy-4,5-dihydro-1,2,4-triazin-3-ylthio)methyl-3-cephem-4-carboxylic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogenchloride; sodium hydrogencarbonate; In tetrahydrofuran; water;	EXAMPLE 17 To 20 ml. of dry THF were added 554 mg. (1.1 mmole) of 7-(alpha-amino)phenylacetamido-3-(4-methyl-5-oxo-6-hydroxy-4,5-dihydro-1,2,4-triazin-3-ylthio)methyl-3-cephem-4-carboxylic acid and 650 mg. (5 mmole) of N-trimethylsilylacetamide. The mixture was stirred for about three hours after which solution was complete. The solution then was cooled to 9 C., and 339 mg. (1.5 mmole) of 1-chloroformyl-3-methanesulfonylimidazolidine-2-one were added. The reaction mixture was stirred for about 30 minutes at 0 C. and then for about 1.5 hours at room temperature. Water (2 ml.) was added to the mixture. The solution then was evaporated in vacuo to an oil. Water (25 ml.) then was added, and the pH of the mixture was raised to 7.5 by addition of sodium bicarbonate. The solution then was washed with ethyl acetate, and the aqueous layer was separated and acidified to pH 1.8 by addition of 1 N hydrochloric acid. The solid which precipitated was filtered and dried to obtain 416 mg. of 7-alpha-(3-methanesulfonylimidazolidine-2-one-1-ylcarbonylamino)phenylacetamido-3-(4-methyl-5-oxo-6-hydroxy-4,5-dihydro-1,2,4-triazin-3-ylthio)methyl-3-cephem-4-carboxylic acid.

Reference： [1]Patent: US4329454,1982,A

25
7-[D-α-amino-α-(2-thienyl)acetamido]-3-(1-methyl-1H-tetrazole-5-yl-thiomethyl)-3-cephem-4-carboxylic acid [ No CAS ]
[ 41762-76-9 ]
UV(methanol) [ No CAS ]
7-[α-[3-(methylsulfonyl)imidazolidine-2-one-1-ylcarbonylamino]α-(2-thienyl)acetamido]-3-(1-methyl-1H-tetrazole-5-ylthiomethyl)-3-cephem-4-carboxylic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In dichloromethane;	EXAMPLE 23 Preparation of 7-[alpha-[3-(methylsulfonyl)imidazolidine-2-one-1-ylcarbonylamino]alpha-(2-thienyl)acetamido]-3-(1-methyl-1H-tetrazole-5-ylthiomethyl)-3-cephem-4-carboxylic acid To a solution of 200 mg. of 7-[alpha-amino-alpha-(2-thienyl)acetamido]-3-(1-methyl-1H-tetrazole-5-ylthiomethyl)-3-cephem-4-carboxylic acid in 25 ml. of dichloromethane were added 2 molar equivalents of triethylamine and a pinch of sodium sulfate. The mixture was filtered and 100 mg. of 3-methylsulfonylimidazolidine-2-one-1-ylcarbonyl chloride were added to the filtrate. The reaction mixture was stirred for 3 hours in a water bath after which the dichloromethane was evaporated. The residue was extracted at pH 2 with ethyl acetate and the extract was washed with water and dried. The dried extract was evaporated in vacuo and the residue recrystallized twice from acetone:diethylether:petroleum ether to yield 109 mg. of the product. UV(methanol): lambda max 270, epsilon 9,328; lambda max 233, epsilon 15,995. NMR(DMSO d6): 3.45 (S, 3H, CH3 SO2 --), 3.65 (AB, 2H, C(2)--H2), 3.8(Broad, 4H, CH2 CH2), 3.95 (S, 3H, tetrazole CH3), 4.6 (AB, 2H, C(3')--H2), 5.05 (d, J=5, 1H, C(6)--H), 5.75 (dd, J=8, J2 =5, 1H, C(7)--H), 5.88 (d, J=7.5, 1H, Side Chain CH), 6.94-7.15 (m, 2H, thiophene aromatic), 7.4-7.5 (dd, 1H, thiophene aromatic), 8.72 (d, J=7, 1H, NH) and 9.51 (d, J=8.5, 1H, NH) delta.

Reference： [1]Patent: US4224442,1980,A

26
[ 72699-65-1 ]
[ 41762-76-9 ]
[ 72699-64-0 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydroxide; In water;	(a) Preparation of 2-(2-oxo-3-methylsulphonyl-imidazolidin-1-yl-carbonylamino)-(5-methyl-isoxazol-3-yl)-acetic acid STR10 1 N Sodium hydroxide solution is added to a suspension of 8.5 g of 2-(5-methylisoxazol-3-yl)-glycine in 150 ml of water until the material has dissolved, and the pH is then brought to 7.6. 12.3 g of 1-chlorocarbonyl-2-oxo-3-methylsulphonyl-imidazolidine are then added in portions, the pH being kept at 7.5-7.7 by dropwise addition of 1 N sodium hydroxide solution. The solution is filtered, acidified and extracted with ethyl acetate. The ethyl acetate phases are dried over sodium sulphate and concentrated. 11.0 g of decomposition point 168 C. result; the material is dried in a high vacuum at 100 C. IR (KBr): 3,326, 1,737, 1,536, 1,396 and 1,168 cm-1.

Reference： [1]Patent: US4235774,1980,A

27
α-amino-α-(2-benzyloxycarbonylamino-thiazol-4-yl)-acetic acid dihydrate [ No CAS ]
[ 41762-76-9 ]
2-(2-Oxo-3-methylsulfonyl-imidazolidin-1-yl-carbonylamino)-2-(2-benzyloxycarbonylamino-thiazol-4-yl)-acetic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In tetrahydrofuran; water;	(a) 2-(2-Oxo-3-methylsulfonyl-imidazolidin-1-yl-carbonylamino)-2-(2-benzyloxycarbonylamino-thiazol-4-yl) acetic acid STR19 The compound is prepared analogously to Example 6 (a) from 15 g of alpha-amino-alpha-(2-benzyloxycarbonylamino-thiazol-4-yl)-acetic acid dihydrate in THF/water (1:1) and 10.9 g 1-chlorocarbonyl-2-oxo-3-methylsulfonyl-imidazolidine in a pH-range from 7.5 to 8.0. 14.1 g (65% of theory) are obtained.

Reference： [1]Patent: US4235774,1980,A

28
[ 41762-76-9 ]
[ 1229649-30-2 ]

Yield	Reaction Conditions	Operation in experiment
	With ammonia;SiO2; In pyridine; methanol; 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran;	Example 18 N-(4-((4-(3-(3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)methyl)pyridin-2-yl)-3-(methylsulfonyl)-2-oxoimidazolidine-1-carboxamide To a solution of Intermediate A (100 mg, 0.192 mmol) in pyridine (1.5 mL) was added <strong>[41762-76-9]3-chlorocarbonyl-1-methanesulfonyl-2-imidazolidinone</strong> (131 mg, 0.576 mmol) in pyridine (1.5 mL) and the reaction mixture was stirred at RT. After 3 days the reaction mixture was evaporated in vacuo and the residue was stirred with NH3 (1% v/v in MeOH). The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (SiO2, 4 g, 100% DCM then 2% MeOH in DCM, isocratic elutions) to afford an impure product which was recrystallized from methanol to give the title compound, Example 18, as a white crystalline solid (12 mg, 9%): m/z 711 (M+H)+ (ES+). 1H NMR (400 MHz, DMSO-d6) delta: 1.27 (9H, s), 2.39 (3H, s), 3.39 (3H, s), 3.87 (4H, s), 5.40 (2H, s), 6.35 (1H, s), 7.01 (1H, d), 7.31 (1H, dd), 7.36 (2H, m), 7.44 (2H, m), 7.55-7.63 (3H, m), 7.93 (1H, m), 8.21 (1H, br s), 8.31 (1H, m), 8.35 (1H, d), 8.58 (1H, br s), 8.79 (1H, br s), 10.40 (1H, br s).

Reference： [1]Patent: US2012/244120,2012,A1

29
[ 1220627-08-6 ]
[ 41762-76-9 ]
[ 1229649-30-2 ]

Yield	Reaction Conditions	Operation in experiment
9%	With pyridine; at 20℃; for 72h;	To a solution of Intermediate A (100 mg, 0.192 mmol) in pyridine (1.5 mL) was added <strong>[41762-76-9]3-chlorocarbonyl-1-methanesulfonyl-2-imidazolidinone</strong> (131 mg, 0.576 mmol) in pyridine (1.5 mL) and the reaction mixture was stirred at RT. After 3 days the reaction mixture was evaporated in vacuo and the residue was stirred with NH3 (1% v/v in MeOH). The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (SiO2, 4 g, 100% DCM then 2% MeOH in DCM, isocratic elutions) to afford an impure product which was recrystallized from methanol to give the title compound, Example 18, as a white crystalline solid (12 mg, 9%): m/z 711 (M+H)+ (ES+). 1H NMR (400 MHz, DMSO-d6) delta: 1.27 (9H, s), 2.39 (3H, s), 3.39 (3H, s), 3.87 (4H, s), 5.40 (2H, s), 6.35 (1H, s), 7.01 (1H, d), 7.31 (1H, dd), 7.36 (2H, m), 7.44 (2H, m), 7.55-7.63 (3H, m), 7.93 (1H, m), 8.21 (1H, br s), 8.31 (1H, m), 8.35 (1H, d), 8.58 (1H, br s), 8.79 (1H, br s), 10.40 (1H, br s).

Reference： [1]Patent: US2016/45512,2016,A1 .Location in patent: Paragraph 0433; 0434

30
C₂₀H₃₆N₂O₂*2ClH [ No CAS ]
[ 41762-76-9 ]
12N-(3-(methylsulfonyl)-2-oxoimidazolidine-1-carbonyl)matrinane hydrochloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
45%	at 20℃;	General procedure: Matrine (5.0 g, 20.0 mmol) was added to 5 N NaOH in water (30 mL), and the reaction mixture was refluxed for 9 h, cooled in an ice bath and then acidified with HCl (2 N) to pH 6-7. The solvent was removed in vaccuo and the residue was dissolved with 2 N HCl in methanol and then heated at refluxing for 2 h. The methanol was removed under reduced pressure to give crude product 2, which was applied directly in the next step without further purification. To a solution of 2 (1.0 eq) in dry CH2Cl2, anhydrous K2CO3 (3.5 eq) and Boc2O (1.5 eq) were added, and the mixture solution was stirred at room temperature until TLC analysis showed completion of the reaction. The reaction mixture was filtered, and the filtrate was washed by water and brine, dried with anhydrous Na2SO4, filtrated and concentrated to afford the crude product 3. To a solution of 3 (1.0 eq) in anhydrous THF (50 mL), a solution of LiAlH4 (1.2 eq) in THF was added in an ice bath, the mixture was stirred at room temperature for 30 min before quenched by acetone, 2 mL of saturated ammonium chloride was added and stirred for 30 min, and the precipitation was filtered off. The filtrate was concentrated to give 4, which was dissolved in CH2Cl2, and TsCl (1.0 eq), TEA (2.0 eq), and dimethylamino pyridine (0.1 eq) were then added to the solution and stirred at room temperature until the TLC showed completion of the reaction. The solution was washed by brine, dried, and concentrated to obtain 5. The compound 6 was obtained from 5 as the same method as 4 from 3. The intermediate 6 was dissolved in 2 N HCl/Et2O (15 mL) and stirred for 30 min to remove the tert-butoxycarbonyl. After reaction completed, the product 7 was obtained as yollow solid by filtration (1.85 g, 30%). To a solution of compound 7 (400 mg, 1.0 eq) in CH2Cl2 or MeCN (30 mL), substituted sulfonyl chloride (1.2 eq), K2CO3 (3.5 eq) were added and stirred at room temperature overnight. After reaction completed, the solvent was removed under reduced pressure and the residue was dissolved with ethyl acetate, washed by brine, dried, filtered and concentrated. The residue was purified by flash column chromatography on silica gel with CH2Cl2/CH3OH as the eluents and then acidized with 2 N HCl/Et2O (1 ml) to give the title compound 8a-h.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2017,vol. 27,p. 829 - 833

31
[ 15401-69-1 ]
[ 41762-76-9 ]
2,3-methylenedioxy-9-((3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)oxy)-10-methoxyprotoberberine chloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
34%		General procedure: BBR (3.71g, 10mmol) was heated at 195-210 C for 10-15 min under vacuum (30-40 mmHg) to afford the black oil, which was acidified with ethanol/concentrated HCl (95:5). The solvent was removed by evaporation, the residue was collected and then purified by flash chromatography over silica gel using CH2Cl2/CH3OH as the gradient eluent, affording the title compound 1 (2.85 g, 80 %) as a yellow solid. To a stirred solution of 1 (100 mg, 0.28 mmol) in anhydrous CH3CN, triethylamine (175 muL, 1.26 mmol) was added and heated to 70C. Then the RCOCl/RSO2Cl (1.1-1.2 eq) was added and stirred for 5-6 h. The mixture was cooled to precipitate completely, filtrated and washed with CH2Cl2 to afford compounds 2a-q and 3a. Compounds 2a-g, 2i, 2n-q and 3a were gained following the same procedure using purchased acyl chloride or sulfuryl chloride as material. Compounds 2h, 2j-m were gained by the same procedure using purchased acid which was reflux in SOCl2 to afford acyl chloride.

Reference： [1]European Journal of Medicinal Chemistry,2018,vol. 143,p. 1858 - 1868

32
14-amino-tetrandrine [ No CAS ]
[ 41762-76-9 ]
14-(1-(methylsulfonyl)imidazolidin-2-one-urea)-tetrandrine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
73.2%	With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃;Inert atmosphere;	General procedure: Carbamoyl chloride (0.19 mmol, 1.2 eq), EDCHCl (0.19 mmol, 1.2eq) and DMAP (0.03 mmol, 0.2 eq) were added into a solution ofC14-amino-tetrandrine 2 (100 mg, 0.16 mmol) in CH2Cl2 (3 mL)under the protection of argon atmosphere and stirred at roomtemperature. After the reaction was completed, the mixture waspoured into a saturated aqueous solution of sodium bicarbonateand extracted three times by dichloromethane. The combinedorganic phase was washed by brine and dried over anhydrousmagnesium sulfate before vacuum suction filtration. The removingof the solvent in vacuo afforded the crude product, which waschromatographied on a silica gel (CH2Cl2/MeOH, 50/1 v/v, 0.1% TEA)to provide compounds 3d, 3e, 3t, 3w and 3x.

Reference： [1]European Journal of Medicinal Chemistry,2018,vol. 143,p. 1968 - 1980

33
[ 1259015-00-3 ]
[ 41762-76-9 ]
2,4-dibromophenazin-1-yl 3-(methylsulfonyl)-2-oxoimidazolidine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
> 99%	With dmap; triethylamine; In dichloromethane; at 20℃; for 2h;	To a stirring solution HP 1A (62.0 mg, 0.18 mmol), triethylamine (48 mu,, 0.35 mmol), and a catalytic amount of 4-dimethlyaminopyridine in dichloromethane (20 niL) was added the acid chloride or carbamoyl chloride reagent (0.35 mmol) at room temperature. The reaction was allowed to stir for two hours before being quenched with an aqueous solution of saturated sodium bicarbonate. The resulting mixture was then transferred to a separatory funnel and ethyl acetate was added to extract the product. The organic layer was sequentially washed with water and brine before being collected. The organic layer was then dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo. The respective ester or carbamate derivative was purified via flash column chromatography using hexanes:ethyl acetate (99: 1 to 80:20) to elute, yielding pure products as yellow solids.2,4-Dibromophenazin-l-yl 3-(methylsulfonyl)-2-oxoimidazolidine-l- carboxylate (76A). Yield: >99%; 95.7 mg was isolated as a pale yellow solid. 1H NMR (600 MHz, CDC13): delta 8.38 - 8.35 (m, 1H), 8.36 (s, 1H), 8.27 (m, 1H), 7.97 - 7.90 (m, 2H), 4.37 - 4.28 (m, 2H), 4.11 (t, J = 7.9 Hz, 2H), 3.45 (s, 3H). 13C NMR (150 MHz, CDC13): delta 149.9, 147.9, 143.9, 143.8, 143.6, 140.3, 137.5, 135.6, 132.6, 132.3, 130.3, 130.0, 123.3, 117.3, 41.6, 41.0, 40.3. HRMS (ESI): calc. for Ci7Hi3Br2N405S [M+H]+: 544.8948, found:544.8949. MP: > 250 C.

Reference： [1]Journal of Medicinal Chemistry,2018,vol. 61,p. 3962 - 3983
[2]Patent: WO2018/152436,2018,A1 .Location in patent: Paragraph 000299, 000378, 000380

34
2-(4-ethoxyphenyl)-1H-pyrrolo[2,3-b]pyridine [ No CAS ]
[ 41762-76-9 ]
1-(2-(4-ethoxyphenyl)-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)-3-(methylsulfonyl)imidazolidin-2-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
23%		2-(4-ethoxyphenyl)-1H-pyrrolo[2,3-b]pyridine (100 mg, 0.42 mmol) was dissolved in anhydrous 22 DMF (5 ml) under argon, treated with 18 NaH (20 mg, 1.2 eq, 0.50 mmol) and stirred at r.t. for 15 min before adding 124 (methylsulfonyl)-2-oxoimidazolidine-1-carbonyl chloride (209 mg, 2.2 eq, 0.92 mmol). The mixture was stirred 6 days at r.t., quenched with water and extracted with EtOAc (4×10 ml). The organic layer was washed with brine, dried over MgSO4, filtered and concentrated. The crude product was purified by flash chromatography (50:50 PE:EtOAc) to afford an oil that was redissolved in 15 CH2Cl2 and concentrated under hi-vacuum to obtain a white 125 solid (41 mg, 23%). (0312) 1H-NMR (300 MHz, CDCl3): 1.44 (t, J=7.0 Hz, 3H), 3.17 (s, 3H), 3.88-3.94 (m, 4H), 4.07 (q, J=7.0 Hz, 2H), 6.60 (s, 1H), 6.95 (d, J=8.7 Hz, 2H), 7.17 (dd, J=7.8, 4.8 Hz, 1H), 7.41 (d, J=8.7 Hz, 2H), 7.88 (dd, J=7.8, 1.5 Hz, 1H), 8.23 (dd, J=4.8, 1.5 Hz, 1H).

Reference： [1]Patent: US2018/312502,2018,A1 .Location in patent: Paragraph 0310-0312

35
3,5-dichlorobenzyl methyl(6-(1,2,3,6-tetrahydropyridin-4-yl)-2,3-dihydro-1H-inden-1-yl)carbamate [ No CAS ]
[ 41762-76-9 ]
C₂₈H₃₀Cl₂N₄O₆S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
35%	With triethylamine; In dichloromethane; at 0 - 20℃;	A solution of Compound 6 (195 mg, 0.452 mmol) in dried CH2CI2 (10 mL) was stirred at 0 C , followed by addition of Et3N (0.13 mL, 0.942 mmol) and 3- chlorocarbonyl-l-methanesulfonyl-2-imidazolidinone (157 mg, 0.678 mmol). The reaction mixture was stirred at room temperature overnight and monitored by TLC. The mixture was added water and extracted with CH2CI2. The organic phase was dried with MgS04 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using CH2Cl2/ethyl acetate =3/1 as elution to yield the desired product of Compound 139 (97 mg, 35%) as a yellow oil.Compound 139, lH NMR (400 MHz, CDCI3) d 7.37-7.20 (m, 6 H), 7.14- 7.11 (m, 1H), 5.94-6.02 (m, 1H), 5.90-5.70 (m, 1H), 5.10-5.24 (m, 2H), 4.19-4.4.15 (m,2H), 3.99-3.72 (m, 4H), 3.60-3.80 (m, 2H), 3.34 (s, 3H), 3.03-2.98 (m, 1H), 2.96- 2.84 (m, 1H), 2.69- 2.66 (m, 4H), 2.50-2.35 (m, 1H), 2.04-1.96 (m,lH). ESI-MS m/z calcd for C28H30CI2N4O6S 620.13, found 643.1 [M+Na]+.

Reference： [1]Patent: WO2019/108943,2019,A1 .Location in patent: Paragraph 0280; 0393-0396

36
[ 85721-33-1 ]
[ 41762-76-9 ]
1‐cyclopropyl‐6‐fluoro‐7‐(4‐(3‐(methylsulfonyl)‐2‐oxoimidazolidine‐1‐carbonyl)piperazin‐1‐yl)‐4‐oxo‐1,4‐dihydroquinoline‐3‐carboxylic acid [ No CAS ]

Reference： [1]Chemical Biology and Drug Design,2019,vol. 94,p. 1518 - 1536

37
[ 41762-76-9 ]
ethyl 1‐cyclopropyl‐6‐fluoro‐7‐(4‐(3‐(methylsulfonyl)‐2‐oxoimidazolidine‐1‐carbonyl)piperazin‐1‐yl)‐4‐oxo‐1,4‐dihydroquinoline‐3‐carboxylate [ No CAS ]

Reference： [1]Chemical Biology and Drug Design,2019,vol. 94,p. 1518 - 1536

38
[ 41762-76-9 ]
1‐cyclopropyl‐6‐fluoro‐3‐(4‐methylpiperazine‐1‐carbonyl)‐7‐(4‐(3‐(methylsulfonyl)‐2‐oxoimidazolidine‐1‐carbonyl)piperazin‐1‐yl)quinolin‐4(1H)‐one [ No CAS ]

Reference： [1]Chemical Biology and Drug Design,2019,vol. 94,p. 1518 - 1536

39
[ 16705-04-7 ]
[ 41762-76-9 ]
2,3,10-trimethoxy-9-(3′-(methylsulfonyl)-2′-oxoimidazolidine-1′-carbonyl)oxyprotopalmatine chloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
43%		General procedure: Triethylamine (1.80 mmol) was added to a stirred solution of 3 (100 mg, 0.40 mmol) inanhydrous CH3CN (6 mL) first, 10 min. later, corresponding acyl chloride (1.2 mmol) or sulfonylchloride (1.2 mmol) were added in the reaction system. The reaction mixture was heated at 65 Cfor 3-8 h. The system was cooled, filtered, and the resulting residue was purified by flashchromatography using CH2Cl2/CH3OH as the gradient eluent, to acquire desired compounds.

Reference： [1]Molecules,2020,vol. 25

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 41762-76-9 ]

Amides

[ 41730-79-4 ]

1-Methanesulfonyl-2-imidazolidinone

Similarity: 0.78

Sulfamides

[ 41730-79-4 ]

1-Methanesulfonyl-2-imidazolidinone

Similarity: 0.78

[ 161357-89-7 ]

1-(Methylsulfonyl)piperazine hydrochloride

Similarity: 0.51

Related Parent Nucleus of
[ 41762-76-9 ]

Imidazolidines

[ 41730-79-4 ]

1-Methanesulfonyl-2-imidazolidinone

Similarity: 0.78

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 41762-76-9 ] {[proInfo.proName]}

Quality Control of [ 41762-76-9 ]

Related Doc. of [ 41762-76-9 ]

Product Details of [ 41762-76-9 ]

Calculated chemistry of [ 41762-76-9 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 41762-76-9 ]

Application In Synthesis of [ 41762-76-9 ]

[ 41762-76-9 ] Synthesis Path-Upstream 1~4

[ 41762-76-9 ] Synthesis Path-Downstream 1~39

Related Functional Groups of [ 41762-76-9 ]

Amides

Sulfamides

Related Parent Nucleus of [ 41762-76-9 ]

Imidazolidines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 41762-76-9 ]

Related Parent Nucleus of
[ 41762-76-9 ]